Literature DB >> 33486005

Synthetic chemical ligands and cognate antibodies for biorthogonal drug targeting and cell engineering.

Pere Monge1, Ane Bretschneider Søgaard1, Dante Guldbrandsen Andersen1, Rona Chandrawati2, Alexander N Zelikin3.   

Abstract

A vast range of biomedical applications relies on the specificity of interactions between an antigen and its cognate receptor or antibody. This specificity can be highest when said antigen is a non-natural (synthetic) molecule introduced into a biological setting as a bio-orthogonal ligand. This review aims to present the development of this methodology from the early discovery of haptens a century ago to the recent clinical trials. We discuss such methodologies as antibody recruitment, artificial internalizing receptors and chemically induced dimerization, present the use of chimeric receptors and/or bispecific antibodies to achieve drug targeting and transcytosis, and illustrate how these platforms most impressively found use in the engineering of therapeutic cells such as the chimeric antigen receptor cells. This review aims to be of interest to a broad scientific audience and to spur the development of synthetic artificial ligands for biomedical applications.
Copyright © 2021 Elsevier B.V. All rights reserved.

Year:  2021        PMID: 33486005     DOI: 10.1016/j.addr.2021.01.010

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  2 in total

Review 1.  Cell-Based Chemical Safety Assessment and Therapeutic Discovery Using Array-Based Sensors.

Authors:  Mingdi Jiang; Aritra Nath Chattopadhyay; Vincent M Rotello
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 5.923

2.  Synthetic Artificial Apoptosis-Inducing Receptor for On-Demand Deactivation of Engineered Cells.

Authors:  Pere Monge; Kaja Borup Løvschall; Ane Bretschneider Søgaard; Raoul Walther; Thaddeus W Golbek; Lars Schmüser; Tobias Weidner; Alexander N Zelikin
Journal:  Adv Sci (Weinh)       Date:  2021-05-01       Impact factor: 17.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.